Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)EBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Zevra Therapeutics (ZVRA) Leases (2018 - 2025)

Zevra Therapeutics' Leases history spans 10 years, with the latest figure at $1.2 million for Q4 2025.

  • For Q4 2025, Leases rose 84.47% year-over-year to $1.2 million; the TTM value through Dec 2025 reached $1.2 million, up 84.47%, while the annual FY2025 figure was $1.2 million, 84.47% up from the prior year.
  • Leases reached $1.2 million in Q4 2025 per ZVRA's latest filing, down from $1.3 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $1.6 million in Q1 2025 to a low of $657000.0 in Q4 2024.
  • Average Leases over 5 years is $1.1 million, with a median of $1.1 million recorded in 2024.
  • Peak YoY movement for Leases: tumbled 36.28% in 2024, then skyrocketed 84.47% in 2025.
  • A 5-year view of Leases shows it stood at $1.1 million in 2021, then fell by 9.64% to $1.0 million in 2022, then changed by 0.0% to $1.0 million in 2023, then tumbled by 36.28% to $657000.0 in 2024, then surged by 84.47% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Leases are $1.2 million (Q4 2025), $1.3 million (Q3 2025), and $1.5 million (Q2 2025).